Abstract:Background: Malignant melanoma is a highly aggressive cancer that presents significant treatment challenges, especially in metastatic stages where conventional therapies often fail due to resistance. Targeting the tumors supportive environment rather than the cancer cells themselves offers a promising strategy. The tumor endothelial marker 8 (TEM8), also known as anthrax toxin receptor 1, is overexpressed in tumor neovasculature endothelial cells and their precursors, making it an attractive therapeutic target. This study introduces PA17, a protein ligand derived from the anthrax toxin binding domain and specifically engineered to target TEM8, aiming to enhance the precision and effectiveness of nanomedicine. Results: Recombinant and purified PA17 ligand protein exhibited high affinity for TEM8 both in vitro and in vivo in preclinical melanoma models, demonstrating significant intrinsic antitumor activity and no detectable off-target effects. When PA17 was used to functionalize doxorubicin-loaded mesoporous silica nanoparticles, it resulted in a 65% reduction in tumor mass with a single local administration and a 55% reduction after three systemic administrations. This treatment was significantly more effective than free doxorubicin or non-targeted doxorubicin-loaded nanoparticles and was associated with a marked decrease in tumor vascularization. Conclusions: This study highlights the potential of toxin-derived ligands as novel targeting agents for tumor neovasculature in aggressive cancers such as malignant melanoma. PA17, with its intrinsic antitumor properties and exceptional targeting efficacy, enhances the efficacy of nanomedicine and addresses common challenges such as drug resistance. The use of natural ligands represents a transformative approach to nanomedicine delivery and offers a promising strategy to advance cancer nanotherapy.

Construction and Evaluation of the Mutated Anthrax Toxin Proteins As Drug Deliver System for Targeting Tumor Cells

Cytotoxicity Modelling of Pasteurella multocida Toxin and Its Histological Study

Engineering an Anthrax Toxin inspired protein-ligand for Nanoparticle-Mediated Treatment of Malignant Melanoma

Construction of site-specific mutants of Staphylococcus enterotoxin A gene and biological activities of recombinant expression products

Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein

Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy

A Microfluidic Live Cell Assay to Study Anthrax Toxin Induced Cell Lethality Assisted by Conditioned Medium

Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin

Acid Active Receptor-Specific Peptide Ligand for in Vivo Tumor-Targeted Delivery

Efficient synthesis and anticancer evaluation of spider toxin peptide LVTX-8-based analogues with enhanced stability

Toxins and Derivatives in Molecular Pharmaceutics: Drug Delivery and Targeted Therapy.

The receptors that mediate the direct lethality of anthrax toxin

The Structure of Tumor Endothelial Marker 8 (TEM8) Extracellular Domain and Implications for Its Receptor Function for Recognizing Anthrax Toxin.

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy

Toward Artificial Immunotoxins: Traceless Reversible Conjugation of RNase A with Receptor Targeting and Endosomal Escape Domains

High-efficiency Protein Delivery into Transfection-Recalcitrant Cell Types.

Spatiotemporally Controllable Diphtheria Toxin Expression Using a Light-Switchable Transgene System Combining Multifunctional Nanoparticle Delivery System for Targeted Melanoma Therapy

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications

Biosynthesis of Multifunctional Transformable Peptides for Inducing Tumor Cell Apoptosis